Get the Stockscreener App
3.01
1.31%
-0.04
Ac Immune Sa stock is traded at $3.01, with a volume of 251.56K.
It is down -1.31% in the last 24 hours and up +9.06% over the past month.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.05
Open:
$3.06
24h Volume:
251.56K
Relative Volume:
0.90
Market Cap:
$306.34M
Revenue:
$4.28M
Net Income/Loss:
$-84.59M
P/E Ratio:
-3.585
EPS:
-0.8396
Net Cash Flow:
$-87.79M
1W Performance:
-0.66%
1M Performance:
+9.06%
6M Performance:
-12.24%
1Y Performance:
+76.02%
1-Day Range:
$3.00
$3.16
1-Week Range:
$2.90
$3.16
52-Week Range:
$1.51
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.01 | 306.34M | 4.28M | -84.59M | -87.79M | -0.8396 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
MSN Money - MSN
AC Immune Releases Q1 2026 Financial Results - AlphaStreet
ACIU Reports Strong Q1 Revenue Growth and Advances Neurodegenera - GuruFocus
AC Immune reports Q1 EPS (15c), consensus (14c) - TipRanks
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline - TipRanks
AC Immune doses first patient in final ABATE trial cohort By Investing.com - Investing.com South Africa
AC Immune doses first patient in final ABATE trial cohort - Investing.com
AC Immune First Quarter 2026 Financial and Corporate Updates - The Manila Times
AC Immune: Q1 Earnings Snapshot - Barchart.com
AC Immune (NASDAQ: ACIU) trims Q1 2026 loss, sees cash runway into Q4 2027 - Stock Titan
AC Immune (NASDAQ: ACIU) triggers $12M Takeda milestone with final ABATE cohort - Stock Titan
AC Immune lines up 3 brain-disease trial readouts for 2026 - Stock Titan
$12M milestone as AC Immune adds final Alzheimer's trial cohort - Stock Titan
AC Immune SA (HAM:IMR) Dividend - GuruFocus
AC Immune SA (HAM:IMR) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling AC Immune SA (HAM:IMR) Stock Today? - GuruFocus
AC Immune SA Stock Baskets - GuruFocus
AC Immune Stock Operating Data - GuruFocus
AC Immune SA (HAM:IMR) Stock Earnings Transcripts - GuruFocus
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
AC Immune SA (HAM:IMR) Stock News, Headlines & Updates - GuruFocus
AC Immune SA (HAM:IMR) Stock HoldersInstitutional & Insider Ownership - GuruFocus
AC Immune SA (HAM:IMR) Competitors 2026 - GuruFocus
AC Immune SA (HAM:IMR)Valuation Measures & Financial Statistics - GuruFocus
ACIU stock rallies 16.3% in a week: Here's what you need to know - MSN
ACIU.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ACIU.O Technical Analysis & Stock Price Forecast - Intellectia AI
AC Immune revises collaboration with Eli Lilly on tau-targeting Alzheimer’s therapy - MSN
ACIU Should I Buy - Intellectia AI
ACIU.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACIU.O PE Ratio & Valuation, Is ACIU.O Overvalued - Intellectia AI
ACIU.O Forecast — Price Prediction for 2026. Should I Buy ACIU.O? - Intellectia AI
Martin Zuegel Net Worth (2026) - GuruFocus
Renee Aguiar Lucander Net Worth (2026) - GuruFocus
Carl Howard June Net Worth (2026) - GuruFocus
Monika Buetler Net Worth (2026) - GuruFocus
Top Executive Makes Notable Move With Fresh AC Immune Stock Sale - TipRanks
Roy Ervin Twyman Net Worth (2026) - GuruFocus
Christopher James Roberts Net Worth (2026) - GuruFocus
Piergiorgio Donati Net Worth (2026) - GuruFocus
Insider Stock Purchases: April 16, 2026 - Moomoo
AC Immune (ACIU) CEO Pfeifer logs 10,000-share sale in amended Form 4 - Stock Titan
AC Immune (ACIU) CEO adds 10,000 shares in open-market buy - Stock Titan
Andrea Pfeifer (NASDAQ: ACIU) plans sale of 10,000 shares under Form 144 - Stock Titan
AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy - Greater Geneva Bern area
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News - Insider Monkey
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):